Obalon Therapeutics Inc represents a values-driven corporate philosophy centered on innovation, patient care, and transformative solutions. As a medical technology company, Obalon is dedicated to providing safe and effective weight loss solutions. The company's commitment to excellence is evident in its FDA-approved, swallowable, and non-surgical weight loss system. Obalon's mission is to address the global obesity epidemic by empowering individuals to achieve their weight loss goals. Through their cutting-edge products and a patient-centric approach, Obalon Therapeutics Inc aims to transform lives and improve overall health and well-being.

Obalon Therapeutics Inc is primarily present in the United States.

Obalon Therapeutics Inc has achieved various significant milestones. The company developed and gained FDA approval for the Obalon Balloon System, a non-surgical weight loss treatment. It also received CE Mark approval for commercialization in Europe. In addition, Obalon entered into collaboration agreements with major pharmaceutical companies and expanded its global footprint. The company successfully conducted clinical studies demonstrating the efficacy and safety of the Obalon Balloon System. Moreover, Obalon Therapeutics Inc has been recognized for its innovations and received prestigious awards. These achievements highlight the company's commitment to revolutionizing weight loss solutions and improving patient outcomes.

Obalon Therapeutics Inc, a renowned medical technology company, specializes in developing and commercializing innovative tools for weight loss. Founded in 2008, Obalon has successfully introduced the Obalon Balloon System, a non-surgical, FDA-approved device designed to assist patients in achieving their weight loss goals. The company is committed to providing effective, safe, and minimally invasive solutions to combat obesity and improve overall patient health. Obalon Therapeutics Inc has grown its presence in the market through extensive research and development, strategic partnerships, and a passion for transforming the lives of individuals struggling with weight management. With its cutting-edge technology and dedication to patient care, Obalon continues to revolutionize the field of weight loss intervention.

The main competitors of Obalon Therapeutics Inc in the market include other companies operating in the medical technology sector, specifically those focused on weight loss solutions. Some notable competitors in this space include EnteroMedics Inc, ReShape Lifesciences Inc, and Medtronic Plc. These companies offer similar non-surgical weight loss treatments and devices, posing potential competition for Obalon Therapeutics Inc. However, it is important to note that market dynamics and competition can change over time, and it is recommended to gather updated information to accurately assess competitors in the market.

Obalon Therapeutics Inc is primarily active in the healthcare and medical devices industry.

Obalon Therapeutics Inc. is a medical technology company that focuses on developing and commercializing innovative products for weight loss. Their business model revolves around the sale of the Obalon Balloon System, a non-surgical, ingestible device designed to help individuals achieve weight loss goals. This system consists of a series of lightweight balloons that are swallowed and then inflated in the stomach to create a feeling of fullness, thereby reducing calorie intake. Obalon Therapeutics Inc. combines this device with a comprehensive weight management program to provide individuals with a safe and effective solution for long-term weight loss.

De K/W-verhouding kan momenteel niet worden berekend voor Obalon Therapeutics.

De KUV kan momenteel niet worden berekend voor Obalon Therapeutics.

De AlleAktien Kwaliteitsscore voor Obalon Therapeutics is 1/10.

De omzet kan momenteel niet worden berekend voor Obalon Therapeutics.

De winst kan momenteel niet berekend worden voor Obalon Therapeutics.

Obalon Therapeutics Inc is a medical technology company that specializes in the development and marketing of innovative weight loss therapy options. The company focuses on non-invasive, minimally invasive, and controlled weight loss and produces and distributes various products for this purpose. The main product of Obalon Therapeutics is the Obalon Balloon System, a non-invasive weight loss system based on the idea that a balloon in the stomach can effectively induce fullness and satiety, reducing the desire for food. The balloon is swallowed under the supervision of medical professionals and then filled with gas to create enough space in the stomach. The balloon in the stomach creates a feeling of fullness, leading the patient to eat less. Obalon Therapeutics' products are primarily aimed at overweight people who have been unsuccessful in reducing their weight through diets and exercise. But also, individuals who are physically unable to perform physically demanding activities such as jogging, training, or other exercises find a meaningful solution in the use of the balloon system. Treatment with the Obalon Balloon System typically lasts three to six months, and the company recommends accompanying diet and exercise therapy to ensure long-term weight loss. Obalon Therapeutics also offers training and education for medical professionals to integrate the balloon system into their practice and pass it on to their patients. In addition, the company provides a program for review and verification to ensure that the prescription and use of the balloon system comply with current regulations. Obalon Therapeutics' business model is designed to benefit both the patient and the medical professionals. Patients receive a non-invasive, easy-to-use weight loss system that is performed under direct medical supervision. At the same time, medical professionals have an innovative and effective tool at hand to help their patients with weight loss while increasing their practice revenue. The company also relies on a comprehensive marketing strategy to promote its products. This includes digital advertising such as online advertising, email campaigns, and social media marketing, as well as participation in medical conferences and events. Overall, Obalon Therapeutics' business model is focused on providing an effective weight loss solution that supports patients in achieving their goals while also providing doctors and medical professionals with an effective tool. With a wide range of products and services tailored to the needs of a growing market, the company has the potential to strengthen its growth and presence in the field of medical weight control.

Obalon Therapeutics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Obalon Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Obalon Therapeutics is US67424L2097.

Het WKN van Obalon Therapeutics is A2PPB1.

De ticker van Obalon Therapeutics is OBLN.

Binnen de laatste 12 maanden betaalde Obalon Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Obalon Therapeutics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Obalon Therapeutics is momenteel .

Obalon Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Obalon Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Obalon Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Obalon Therapeutics van 4-10-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 4-10-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 4-10-2024.

In het jaar 2023 heeft Obalon Therapeutics 0 USD aan dividenden uitgekeerd.

De dividenden van Obalon Therapeutics worden in USD uitgekeerd.